Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Related Citations for PubMed (Select 17192389)

1.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

2.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

3.

Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW.

J Exp Med. 1998 Jun 1;187(11):1893-902.

4.

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R.

Blood. 2005 May 1;105(9):3737-42. Epub 2005 Jan 11.

5.

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG.

Blood. 2009 Apr 30;113(18):4414-24. doi: 10.1182/blood-2008-10-182626. Epub 2009 Jan 29.

6.

Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.

Dobbin E, Graham C, Corrigan PM, Thomas KG, Freeburn RW, Wheadon H.

Exp Hematol. 2009 Jan;37(1):111-121. doi: 10.1016/j.exphem.2008.09.012.

PMID:
19100521
7.

Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.

Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC, Wang J, Ranheim E, Zhang L, Chang YI, Ryu MJ, Zhang JF, Zhang J.

Leukemia. 2013 Mar;27(3):754-7. doi: 10.1038/leu.2012.251. Epub 2012 Aug 31. No abstract available.

8.

PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.

Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K.

Sci Signal. 2013 Dec 3;6(304):ra105. doi: 10.1126/scisignal.2004125.

9.

In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.

Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM.

Blood. 1999 Oct 1;94(7):2469-76.

10.

Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.

Heuser M, Sly LM, Argiropoulos B, Kuchenbauer F, Lai C, Weng A, Leung M, Lin G, Brookes C, Fung S, Valk PJ, Delwel R, Löwenberg B, Krystal G, Humphries RK.

Blood. 2009 Nov 5;114(19):3983-93. doi: 10.1182/blood-2009-06-227603. Epub 2009 Aug 10.

11.

Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.

Buitenhuis M, Verhagen LP, Cools J, Coffer PJ.

Cancer Res. 2007 Apr 15;67(8):3759-66.

12.

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG.

J Clin Invest. 2004 Feb;113(4):528-38.

13.

Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis.

Kato Y, Iwama A, Tadokoro Y, Shimoda K, Minoguchi M, Akira S, Tanaka M, Miyajima A, Kitamura T, Nakauchi H.

J Exp Med. 2005 Jul 4;202(1):169-79.

14.

Oncostatin M-mediated regulation of KIT-ligand-induced extracellular signal-regulated kinase signaling maintains hematopoietic repopulating activity of Lin-CD34+CD133+ cord blood cells.

Oostendorp RA, Gilfillan S, Parmar A, Schiemann M, Marz S, Niemeyer M, Schill S, Hammerschmid E, Jacobs VR, Peschel C, Götze KS.

Stem Cells. 2008 Aug;26(8):2164-72. doi: 10.1634/stemcells.2007-1049. Epub 2008 May 22.

15.

Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.

Medves S, Noël LA, Montano-Almendras CP, Albu RI, Schoemans H, Constantinescu SN, Demoulin JB.

Haematologica. 2011 Oct;96(10):1406-14. doi: 10.3324/haematol.2011.040147. Epub 2011 Jun 17.

16.

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS.

Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069.

17.

Brain cancer stem-like cell genesis from p53-deficient mouse astrocytes by oncogenic Ras.

Lee JS, Gil JE, Kim JH, Kim TK, Jin X, Oh SY, Sohn YW, Jeon HM, Park HJ, Park JW, Shin YJ, Chung YG, Lee JB, You S, Kim H.

Biochem Biophys Res Commun. 2008 Jan 18;365(3):496-502. Epub 2007 Nov 20.

PMID:
18021740
18.

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.

Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E 3rd, Zhang Y.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63. Epub 2007 Oct 2. Erratum in: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19655.

19.

Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.

Cho HC, Lai CY, Shao LE, Yu J.

Cancer Res. 2011 Dec 1;71(23):7250-8. doi: 10.1158/0008-5472.CAN-11-0903. Epub 2011 Nov 16.

20.

Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult.

Motoda L, Osato M, Yamashita N, Jacob B, Chen LQ, Yanagida M, Ida H, Wee HJ, Sun AX, Taniuchi I, Littman D, Ito Y.

Stem Cells. 2007 Dec;25(12):2976-86. Epub 2007 Sep 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk